Because numerous studies have revealed that the dosage of PMP22 may determine the type and severity of the related neuropathy, such as CMT or HNPP, treatment strategies should target the direct pathways affected by the PMP22 gene dosage. The gene discussed is PMP22; the disease is neuropathy.